indinavir

indinavir is a potent protease inhibitor antiretroviral medication used as part of combination therapy for the treatment of HIV/AIDS. It was developed by the pharmaceutical company Merck & Co. and received accelerated approval from the U.S. Food and Drug Administration in 1996. The drug works by selectively inhibiting the HIV-1 protease enzyme, thereby preventing the cleavage of viral polyproteins and the production of mature, infectious virions. While its use has declined with the advent of newer agents with better tolerability, indinavir played a pivotal role in establishing the viability of highly active antiretroviral therapy (HAART).

Medical uses

Indinavir is indicated for the treatment of HIV-1 infection in adults and children over the age of four, always in combination with other antiretroviral agents such as nucleoside reverse transcriptase inhibitors. Its use is guided by genotypic resistance testing to assess for viral susceptibility, as resistance can develop. The drug was a cornerstone of early HAART regimens, often paired with medications like zidovudine and lamivudine. Due to its pharmacokinetic profile, it must be administered on a strict schedule, typically every eight hours, and requires adequate hydration to mitigate the risk of nephrolithiasis.

Adverse effects

The adverse effect profile of indinavir is significant and contributed to its declining use. A hallmark toxicity is the formation of kidney stones (nephrolithiasis) and crystalluria, attributed to the drug's poor solubility. Other common effects include gastrointestinal disturbances such as nausea and diarrhea. A distinct syndrome of metabolic complications emerged, including lipodystrophy, hyperglycemia, and new-onset diabetes mellitus. It can also cause hyperbilirubinemia, manifesting as asymptomatic jaundice, and was associated with rare cases of acute hemolytic anemia.

Pharmacology

Indinavir functions as a competitive inhibitor of the HIV-1 protease enzyme, binding reversibly to the active site with high affinity. This inhibition prevents the post-translational processing of gag-pol polyproteins, leading to the production of immature, non-infectious viral particles. The drug is rapidly absorbed after oral administration, but its absorption is significantly reduced by food, requiring administration on an empty stomach or with a light, low-fat meal. It is extensively metabolized in the liver by the cytochrome P450 system, primarily via the CYP3A4 isoenzyme, and is a known inhibitor of this pathway, leading to numerous drug-drug interactions.

History

The discovery of indinavir was a landmark achievement in antiviral drug development during the early 1990s. Researchers at Merck & Co., building on the elucidation of the HIV protease structure by scientists at the National Institutes of Health and elsewhere, utilized structure-based drug design to optimize the compound, initially coded L-735,524. Its clinical development was expedited due to the urgent need for effective AIDS therapies, culminating in its accelerated approval by the FDA in March 1996. The drug's introduction, alongside other protease inhibitors like ritonavir and saquinavir, dramatically transformed HIV/AIDS from a terminal illness into a manageable chronic condition.

Society and culture

Indinavir, marketed under the trade name Crixivan, had a profound cultural and societal impact following its approval. It was a central component of the "Lazarus syndrome" phenomenon, where severely ill AIDS patients experienced dramatic recoveries. The drug's high cost and complex dosing regimen highlighted issues of healthcare access and adherence within the global HIV/AIDS epidemic. Its development story was featured in prominent media, including The New York Times, and became a symbol of the rapid progress in biomedical research during the 1990s. The legacy of indinavir is evident in modern antiretroviral therapy, which favors once-daily, better-tolerated regimens pioneered by this first generation of protease inhibitors.

Category:Antiviral drugs Category:Protease inhibitors Category:HIV/AIDS